Nathalie Roders, PhD
Senior Research Scientist
Nathalie Roders has over 10 years of experience in academic research, focusing her research on immunology and oncology, before joining Emglev Therapeutics now ValourBio. She completed a postdoctoral position at Hôpital St. Louis in Paris, focusing on Chimeric Antigen Receptor (CAR) T-cell therapy and CRISPR/Cas9 genome editing. She holds a PhD in molecular and cellular aspects in Biology, during which she investigated the role of antibodies in transplanted organ rejection and B cell receptor signaling in B-cell lymphoma survival.